Related Experiment Videos
[Immunoadsorption using Staphylococcus aureus, COWAN I strain].
Zeitschrift Fur Urologie Und Nephrologie
|August 1, 1983
Summary
Immunoadsorbents utilizing protein A selectively bind IgG, offering potential therapeutic applications for antibody-mediated diseases. Further research is needed to address complement activation challenges for clinical use.
Area of Science:
- Biomedical Engineering
- Immunology
- Materials Science
Context:
- Immunoadsorbents offer a novel therapeutic approach for diseases driven by antibodies or immunocomplexes.
- They are being explored as an alternative or adjunct to plasmapheresis-plasma exchange.
- Protein A-bearing staphylococci (strain COWAN I) are investigated for their immunoglobulin-binding capabilities.
Purpose:
- To evaluate the in vitro binding characteristics of protein A-bearing staphylococci for various immunoglobulins and plasma proteins.
- To assess the potential of these immunoadsorbents in clinical applications for immune-related disorders.
Summary:
- Protein A-bearing staphylococci selectively bind IgG, with minimal binding of IgA, IgD, and IgE, and some IgM binding.
- Non-specific binding of other plasma proteins like albumin and transferrin is minimal.
- Acidic solutions can elute bound proteins, but complement system activation by IgG-protein A interaction remains a challenge.
Impact:
- Protein A immunoadsorbents show promise for targeted removal of pathogenic immunoglobulins.
- Addressing complement activation is crucial for the safe and effective clinical translation of these immunoadsorbent therapies.
- This research could pave the way for new treatments in autoimmune and immune-complex-mediated diseases.